Crinetics Pharmaceuticals (CRNX) EBITDA (2017 - 2026)
Crinetics Pharmaceuticals (CRNX) EBITDA from Jun 30, 2017 to Mar 31, 2026. The TTM Crinetics Pharmaceuticals (CRNX) EBITDA is -$542M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Crinetics Pharmaceuticals (CRNX) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +45.01% |
| 3 Years TTM | +44.10% |
| 5 Years TTM | +46.91% |
| All Time TTM | +61.12% |
Annual EBITDA change of Crinetics Pharmaceuticals (CRNX)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$139M | -72.85% |
| 2025 | -$513M | +52.62% |
| 2024 | -$336M | +51.71% |
| 2023 | -$222M | +32.72% |
| 2022 | -$167M | +56.30% |
| 2021 | -$107M | +44.30% |
| 2020 | -$74M | +39.78% |
| 2019 | -$53M | +87.46% |
| 2018 | -$28M | +213.78% |
| 2017 | -$9M | +51.26% |
| 2016 | -$5.95M | N/A |
Comparison Crinetics Pharmaceuticals (CRNX) five years EBITDA CAGR with competitors
Crinetics Pharmaceuticals (CRNX) five years EBITDA CAGR is 46.91%.